The call, on record
MRNA bearish call
Target Price
$140
Quoted text as recorded“this meeting on Saturday could go horrible for Mona and then it's $140 stock again and you've lost all your gains.”@ 12:41 · open at this moment on YouTube ↗
Our interpretation
- Source published
- Oct 20, 2026
- Timeframe
- Conditional on a disappointing presentation this Saturday, October 24; no explicit price deadline.
- Stored reference price
- $226.89
- Interpreted confidence
- low
- Specificity
- specific
Why this call is unscored
- Status
- Not scored
- Notes
- [deadline_review] Deadline requires review (ambiguous_window).
Email me when MRNA calls resolve
When a tracked MRNA call is scored — hit, miss or partial — we’ll email you the result. No account needed.
Used only for these updates. Privacy
Our summary of the thesis
BullishStructured interpretation of the video, not a verbatim quotation. Check the source for conditions, emphasis and context.
The host is enthusiastic about Moderna's personalized cancer therapy and the potential for AI to accelerate treatment development and broaden access. He presents the October 24 presentation as a major catalyst with sharply different upside and downside outcomes.
Key arguments
- AI can accelerate identification of cancer-specific targets and increase the number of targets used in personalized treatment.
- Faster processing could reduce costs and enable more patients to receive treatment.
- The therapy could potentially expand to additional cancers.
- The upcoming presentation could support renewed investor interest after the decline of Moderna's COVID-related growth.
- The host owns Moderna and describes buying around the $135–$145 area.
Counter-arguments acknowledged
- The presentation could deliver bad news.
- The investment depends heavily on one treatment and carries substantial clinical trial risk.
- A disappointing presentation could erase recent stock gains.
- The $220 target mentioned is Bank of America's target, not an independently adopted host target.
Hedges and caveats (from the video)
- Moderna's presentation could disappoint, causing substantial losses.
- Moderna has concentrated exposure to a single treatment and significant trial risk.
- Tempus AI's reported profit largely reflected stock investment gains rather than underlying operating profitability.
- The host considers it too early to identify Tempus AI as a winner in healthcare data and applications.
- The host discloses exposure to two of the three featured companies and explicitly confirms holding Moderna.
- The discussion is not personalized financial advice.
About this record
Not yet reviewed by a moderatorImported analysis · scheduled AI source. A quote, summary and outcome each need their own context. Moderator review does not certify investment performance.
- Source published
- Oct 20, 2026, 9:26 PM UTC
- First recorded by TubeRank
- Oct 20, 2026, 9:42 PM UTC
- Record last updated
- Oct 20, 2026, 9:42 PM UTC
- Moderator review recorded
- Not recorded
- Transcript provenance
- YouTube captions (manual or automatic)
- Recorded analysis processor/source label
- codex-cli-scheduled
- This can identify a workflow rather than an exact AI model version.
- Submission path version
- manual_v1
- Identifies the precomputed submission path. It does not identify an AI model version or imply human authorship.
- Outcome methodology version
- Not recorded; not audited under current rules
Recent record changes 1 shown
Oct 20, 2026, 9:42 PM UTC
source updated
- Recorded analysis processor/source label
BeforeNot recorded
Aftercodex-cli-scheduled
- Extraction or submission version
BeforeNot recorded
Aftermanual_v1
Showing up to 20 recent changes. The complete feed has 2 recorded events for this call, including its initial entry. Read the full paginated history (JSON); follow nextCursor while hasMore is true.
Stored outcome evidence
- Stored reference price
- $226.89
- Oct 19, 2026, 11:59 PM UTC · yahoo_daily
- Target as extracted
- $140
- Stated deadline as extracted
- None recorded
- Recorded outcome date
- Not recorded
- Outcome price observation
- Not recorded
- Not recorded · provider not recorded
Stored explanation
[deadline_review] Deadline requires review (ambiguous_window).
Missing timestamps, providers and versions are historical gaps. Stored observations can include daily closes; they do not show every intraday touch or prove an executable trade. Read the methodology.
Why we interpreted the confidence this way
The host describes a possible adverse outcome rather than his base case. Conditional framing and 'could' reduce conviction.